The transaction details are sourced from an SEC EDGAR filing published on May 1, 2026. The specific form type is not identified in the available documentation. The deal is currently in pending regulatory status, meaning all material conditions to closing have not yet been satisfied and the transaction has not closed.
Centerview Partners has been retained as exclusive financial advisor to Esperion, the target company, in a lead advisory role. On the acquirer side, Moelis & Company LLC is serving as exclusive financial advisor to ARCHIMED in a lead capacity. For debt financing, investment funds managed by Pharmakon Advisors, LP are providing debt financing for the transaction, positioning Pharmakon in a financing provider role.
Goodwin Procter LLP is serving as legal counsel to Esperion Therapeutics. Sidley Austin LLP has been engaged as legal advisor to ARCHIMED. Akin Gump LLP is providing legal advisory services to Pharmakon Advisors, the debt financing provider.
The transaction is structured as an acquisition with a disclosed equity value of $1,100,000,000. Debt financing has been committed by Pharmakon Advisors' investment funds, indicating a leveraged component to the overall financing structure. Beyond this confirmation of debt involvement, no further details have been disclosed regarding the specific mix of debt and equity consideration, the amount or terms of any debt facility, interest rates, maturity dates, or other financing terms.
Several material facts remain undisclosed or unknown at this time. No expected closing date or regulatory timeline has been provided. The consideration structure (whether cash at close, the role of any escrow, earn-outs, or other adjustments) is not specified. The specific amount of debt financing relative to equity has not been disclosed. Additionally, the regulatory approvals required and the current status of those approvals beyond the general "pending regulatory" designation are not detailed in the available documentation.